{"abstract":"The National Cancer Institute (NCI), an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to StraightLine Bio, Inc. located in Princeton, New Jersey.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2024/12/11/2024-29076.html","cfr_references":[],"citation":"89 FR 99888","comment_url":null,"comments_close_on":"2024-12-26","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before December 26, 2024 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2024-29076","effective_on":null,"end_page":99888,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2024/12/11/2024-29076.xml","html_url":"https://www.federalregister.gov/documents/2024/12/11/2024-29076/prospective-grant-of-an-exclusive-patent-license-anti-kk-lc-1-t-cell-receptors-for-the-treatment-of","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2024-29076?publication_date=2024-12-11","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2024-12-11/2024-29076/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":147,"last_updated":"2026-10-24 06:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-12-11/pdf/2024-29076.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-29076.pdf?1733838331","publication_date":"2024-12-11","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2024/12/11/2024-29076.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2024-12-11T09:06:48Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":99888,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Anti-KK-LC-1 T Cell Receptors for the Treatment of Cancer","toc_doc":"Anti-KK-LC1 T Cell Receptors for the Treatment of Cancer","toc_subject":"Licenses; Exemptions, Applications, Amendments, etc.","topics":[],"type":"Notice","volume":89}